Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Lack of such T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhaoming, Yin, Chaobo, Lum, Lawrence G., Simons, Andrean, Weiner, George J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656063/
https://www.ncbi.nlm.nih.gov/pubmed/34886888
http://dx.doi.org/10.1186/s13045-021-01216-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656063/
https://www.ncbi.nlm.nih.gov/pubmed/34886888
http://dx.doi.org/10.1186/s13045-021-01216-w

Ejemplares similares